Alexa
  • Directory of Taiwan

Taiwan takes 3 million blood pressure tablets off shelves due to cancer risk

Taiwanese manufacturer found traces of NDEA in tablets

  1331
Cosar blood pressure tablets (photo courtesy of FDA).

Cosar blood pressure tablets (photo courtesy of FDA). (CNA photo)

TAIPEI (Taiwan News) - The Food and Drug Administration (FDA) said Saturday it was taking 3.22 million tablets of the blood pressure drug Cosar (脈莎平膜衣錠50毫克) off shelves due to the potential presence of a cancer-causing ingredient.

The Chiayi City-based manufacturer of the Cosar F.C. Tablets 50 mg, Shou Yuan Chemical Industries (壽元化學工業公司), had conducted tests on its own products and found the presence of NDEA, a potentially carcinogenous substance, the Central News Agency reported. As a result, the company alerted the FDA and launched a recall.

The recall affected 11 batches totaling 3.22 million tablets designed to lower blood pressure and would be completed within a month, FDA officials said.

Last July, cancer-causing elements such as NDEA and NDMA were first found in tablets produced in China and India, leading to greater international caution and more stringent checks of blood pressure drugs, according to the CNA report.

Patients using the drugs should not stop treatment but first consult their physicians to seek alternative drugs for their blood pressure problems, FDA officials said.


Updated : 2021-08-02 07:23 GMT+08:00